Medizone Intl. (fka MZEIQ)

[Tane61]

MZEIQ: Here is an even better idea .....

..... stop fantasizing about Medizone's FLAWED, gaseous ozone based wound healing, Intellectual Property. BTW, Toxic/Corrosive gaseous ozone is anathema!

correction: Medizone owns no Intellectual Property, FLAWED or otherwise

https://www.courtlistener.com/recap/gov.uscourts.nvb.372229/gov.uscourts.nvb.372229.86.0.pdf

----------

Another great idea: Aqueous Oxygen Peroxide (AOP) available/unavailable from Bioquell rather than gaseous ozone never available/unavailable from bankrupt Medizone

BioxyQuell – novel, topical treatment of wounds Bioquell has been developing BioxyQuell (“BxQ”), Bioquell’s novel peroxy-chemistry based wound treatment technology for a number of years. The technology has regulatory approval in the EU and we have been working on the commercialisation of BxQ in the UK. Over recent years the bio-chemistry of wound healing has become better understood. In particular, it is increasingly clear that biofilms can significantly hinder wound healing or cause major clinical issues in certain procedures. Moreover, biofilms have been shown to stop wounds healing, giving rise to chronic wounds. Given the increasing issues with antimicrobial resistance, we believe that there are substantial opportunities for our BxQ technology – as it appears to be efficacious against biofilms and assists in the treatment of chronic wounds. However, unfortunately we have found it difficult to commercialise this technology in the current hospital funding environment and we have decided to ‘mothball’ the technology as we believe we have better commercial opportunities within our portfolio of products and services. Accordingly the Board has decided to impair the value of the capitalised development costs of this technology (which was announced at the beginning of 2015). Notwithstanding this (non-cash) impairment, we continue to believe that as antimicrobial resistance becomes more problematic our BxQ technology may have an important role to play

http://www.bioquellplc.com/downloads/reports/AR_2014.pdf

----------

Publication of BioxyQuell randomised controlled clinical trial - Published on 28th April 2014

A 3-year gold-standard, randomised, placebo-controlled, double-blind clinical trial investigating the efficacy of the BioxyQuell wound treatment system has been published in the Journal of Wound Care. The study was conducted in primary care through four Hampshire based GP surgeries, providing a “real world” assessment of the technology.

Patients suffering with chronic, static, non-healing venous leg ulcers (VLUs) were treated with either a 20 part per million aqueous oxygen peroxide (AOP) solution or a sterile water placebo. Patients received six fifteen minute treatments over a period of two weeks, with follow-up observations over 12 months. Patients were blind to the treatment they received as were assessing clinicians.

The results of the study identified statistically significant differences in wound size reduction, reduction in microbiological organisms, reduction in pain and long term healing outcomes, all in favour of AOP treatment. Patients treated with AOP were statistically less likely to develop an infected wound than patients treated with the placebo. Investigators found that 100% of patients treated with AOP and whom successfully completed the study healed within 12 months, compared to 53% of placebo patients. Patients also reported large reductions in pain during the two week period of AOP treatment.

John Chewins, BioxyQuell Product Manager said “We are very pleased with the outcomes of the trial, which clearly show the advantages of treating patients with the BioxyQuell system”.

http://healthcare.bioquell.com/en-uk/media-centre/latest-news/healthcare/publication-bioxyquell-randomised-controlled-clinical-trial